Novasep and Triclinic Labs to jointly develop solid-state chemistry services

Novasep, the French supplier of services and technologies for the life sciences industry, has formed a partnership with Triclinic Labs Inc, the US-based provider of contract pharmaceutical and fine chemical solid-state development services. This is Novasep’s first partnership agreement focusing on early-stage, solid-state services. Those services will be in addition to Novasep’s existing, early-stage, active pharmaceutical ingredient (API) synthesis and purification services and made available to customers in North America as well as other regions.

The newly formed alliance between Novasep and Triclinic Labs will enable both parties to offer their customers a full API development service, ranging from first chemical synthesis to solid form optimisation. Novasep’s services will be extended to include solid form screening, selection, development, characterisation and analytical method development.

“This alliance was designed from the ground up to benefit companies who want a seamless handoff between development and scale up. While there are numerous synthesis companies and early stage development groups, this alliance is distinctive as it pairs two leading companies with extensive, unique and demonstrated physical and analytical chemistry capabilities. We can now offer world-class large and small molecule screening, characterisation, purification, control, scale up, method development/validation and intellectual property support capabilities,” said Dr David Bugay, CSO of Triclinic Labs.

While the efficiency of a drug is based on its intrinsic nature and its interactions with biological targets, the preparation process has a strong impact on these properties. Finding the most appropriate solid phase can optimise these features. The best solid phase - be it a crystalline polymorph, salt, cocrystal or amorphous form - can maximise physicochemical properties and therefore improve drug efficiency.

“This new partnership with Triclinic Labs is a further step in our ‘Back to Basics’ strategic plan. It enables us to expand our offering to our clients by adding services onto the last stage of product development,” said Dr Michel Spagnol, CEO of Novasep.

Andrew Brennan, general manager at Novasep’s US operations, added, “The alliance with Triclinic Labs emphasises our continued commitment towards the North American market, following the recent opening of our US-based synthesis laboratory and kilo lab in Boothwyn, PA.”